您的位置: 首页 > 农业专利 > 详情页

Predicting response to a VEGF antagonist
专利权人:
Inc.;Genentech
发明人:
Xiao, Yuanyuan,Bais, Carlos,Choi, Younjeong,Consalvo, Nicola C.
申请号:
AU2015346652
公开号:
AU2015346652A1
申请日:
2015.11.09
申请国别(地区):
AU
年份:
2017
代理人:
摘要:
The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充